SpecificationsOrganism/cell line/tissueMus musculus/C2C12 myoblastsSequencer or array typeAffymetrix GeneChip Mouse Gene 2.0ST Arrays scanned by Affymetrix GeneChip Scanner 3000Data formatRaw CEL files and RMA summaryExperimental factorsTumorigenic vs. control cellsExperimental featuresGenetic silencing of Cox4i1 by shRNA induced a tumorigenic phenotype in C2C12 myoblasts, the mRNA expression of which was compared to the control with scrambled shRNA

1. Direct link to deposited data {#s0005}
================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68525>

2. Direct link to deposited source codes {#s0010}
========================================

<http://code.vet.upenn.edu/download/CcOdefect/>

3. Experimental Design, Materials and Methods {#s0015}
=============================================

3.1. Sample preparation {#s0020}
-----------------------

Cells were grown in Dulbecco\'s Modified Eagle medium supplemented with 10% fetal bovine serum and 0.1% penicillin/streptomycin. In case of Cox4i1 silenced (C4KD) cells, the medium was further supplemented with 1 mM Pyruvate and 50 μg/ml Uridine. RNA was prepared using Qiagen Rneasy kit following manufacturer\'s instructions. 5.5 μg single-stranded cDNA was fragmented and labeled using the Affymetrix GeneChip WT Terminal Labeling kit (PN: 900671). Labeled cDNA (3.25 μg) was hybridized for 17 h at 45°C to Affymetrix GeneChip Mouse Gene 2.0ST Arrays (PN: 902118).

3.2. Microarray analysis {#s0025}
------------------------

The data were processed by Affymetrix Expression Console using Probeset-Summarize-Engine with default setting of the robust multi-array average (RMA, [@bb0005]) method to calculate the expression level for each probeset of the array (in *log*~2~ unit, online file: rma-gene-full.summary.txt). For quality control, we performed principal component analysis (PCA) based on RMA expression levels of the samples. The projection to the most dominant two components is shown in [Fig. 1](#f0005){ref-type="fig"}a. The control samples formed a single cluster separable from the knockdown. However, the knockdown samples are further branched into two groups. The grouping is also clearly shown ([Fig. 1](#f0005){ref-type="fig"}b) by the correlation coefficient value (with each probe mean over all samples removed) between two samples: if the two samples come from the same group, the value is high (above 0.6); if they come from different groups, the value is low or negative. Further investigation of the biological samples showed that C4KD1 and C4KD2 cells contained nearly 90% reduced Cox4i1 mRNA and protein as compared to control cells [@bb0010], while in C4KD3 cells the reduction was not as much (probably due to a less effective population selection by antibiotic resulting a mixture of knockdown and non-knockdown cells). This is consistent with microarray results: for both C4KD1 and C4KD2 the reduction were \~ 20 folds, for C4KD3 only \~ 2 folds. In the following analysis, C4KD3 was excluded.

3.3. Statistical analysis {#s0030}
-------------------------

Fold changes are presented as the mean ± s.e.m. (standard error of the mean) and *p*-values were determined by one-tailed Welch\'s t-test, which is used to test the hypothesis that two populations have equal means and is more reliable than Student\'s t-test when the samples from two populations have unequal variances and unequal sample sizes [@bb0015]. So for a statistic *t* and a degrees of freedom *v*, the *p*-value is calculated by$$\frac{1}{2}I_{\frac{v}{v + t^{2}}}\left( {\frac{v}{2},\frac{1}{2}} \right)$$

where *I* is the regularized incomplete beta function. The statistic *t* is defined by the following formula:$$t = \frac{m_{1} - m_{2}}{\sqrt{s_{1} + s_{2}}}$$

where *m*~1~ and *s*~1~ are the mean and the s.e.m of the 1st sample, and *m*~2~ and *s*~2~ of the 2nd sample. The degrees of freedom *v* is approximated by$$v \approx \frac{\left( {s_{1}^{2} + s_{2}^{2}} \right)^{2}}{\frac{s_{1}^{4}}{v_{1} - 1} + \frac{s_{2}^{4}}{v_{2} - 1}}$$

where *v*~1~ and *v*~2~ are the 1st and 2nd sample size, respectively. All calculations are performed using RMA expression levels, i.e., in *log*~2~ unit. For a given gene, a fold change \> 2^0.5^ with a *p*-value \< 0.05 was considered statistically significant. [Fig. 1](#f0005){ref-type="fig"}b shows the distribution of fold change versus *p*-value for the full probeset of the Affymetrix GeneChip Mouse Gene 2.0ST Arrays. Out of 41,345 probes, 6049 had statistically significant fold change (red dots in [Fig. 1](#f0005){ref-type="fig"}c). Among those are 4908 uniquely identified genes (out of 26,515 Entrez genes of the array). Each individual gene expression presented in the paper is among those.

3.4. Pathway analysis {#s0035}
---------------------

The list of genes with significant fold change was uploaded to KEGG Mapper to search pathways (<http://www.genome.jp/kegg/tool/map_pathway1.html>, [@bb0020]). To further narrow down the list of pathways, we calculated the *p*-value of pathway enrichment. With *H* the hits, i.e., the number of genes from our list present in a pathway of size *S*, *N* the number of genes of the list, and *T* the total number of genes of the array, the enrichement *p*-value was determined by$$1 - F\left( {{H - 1};T,S,N} \right)$$

in which *F*(*h*; *t*, *s*, *n*) is the hypergeometric cumulative distribution function$$F\left( {h;t,s,n} \right) = {\sum\limits_{i = 0}^{i = h}\frac{\left( {}_{i}^{s} \right)\left( {}_{n - i}^{t - s} \right)}{\left( {}_{n}^{t} \right)}}$$

We found *N* = 4908, used *T* = 26515 and retrieved *S* from the KEGG database (July, 2015). [Table 1](#t0005){ref-type="table"} shows the top 64 most enriched pathways---excluding the ones in organ functions and specific diseases.

3.5. Functional analysis {#s0040}
------------------------

A more stringent criteria was used to select genes for functional annotation: a fold change \> 2 with a *p*-value \< 0.01. There were 1861 probes satisfied this criteria. To control the false discovery rate (FDR), the Benjamini-Hocheberg procedure [@bb0025] was applied to select further: for the FDR at level *q*, find the largest *k* such that$$p_{k} \leq \frac{k}{m}q$$

then select *i* = 1\...*k*, where *p*~*k*~ is the *p*-value of *m* genes with lowest *p*-values. For a FDR of 0.01, 1860 out 1861 probes were selected ([Fig. 1](#f0005){ref-type="fig"}d). Among those were 656 up-regulated and 391 down-regulated uniquely identified genes (see files mypup.txt.2x0.01p and mypdown.txt.2x0.01p). The generated gene list was functionally annotated using DAVID 6.7 (<http://david.abcc.ncifcrf.gov>/, [@bb0030]) with default setting (online file: myfa_table_all.txt.2x0.01p). The functional groups of genes were extracted from the annotated file using the corresponding terms (e.g. "signal transduction,") with our own script (online file: myfa.csh).

4. Results {#s0045}
==========

4.1. Enriched expression in metabolic, cancer and PI3K signaling pathways {#s0050}
-------------------------------------------------------------------------

Metabolic Pathways, Pathways in Cancer and PI3K-Akt Signaling Pathway were the top three pathways enriched with the genes of significant expression change due to the CcO complex defect ([Table 1](#t0005){ref-type="table"}). Among the three, Pathways in Cancer and PI3K-Akt Signaling Pathway had a lots of overlaps while they had little overlaps with Metabolic Pathways ([Fig. 2](#f0010){ref-type="fig"}a). The 330 genes enriching Metabolic Pathways were distributed in different pathways of metabolism ([Fig. 2](#f0010){ref-type="fig"}b). Oxidative Phosphorylation was the leading one. Another enriched one was Glycolysis/Gluconeogenesis. Glycolysis is known to be responsible for energy generation if Oxidative Phosphorylation is interrupted. The 127 genes enriching Pathways in Cancer were sub-divided into many pathways ([Fig. 2](#f0010){ref-type="fig"}c). Interestingly, genes in PI3K-Akt Signaling Pathway accounted for one third overall and contributed about half to others except Wnt and Hippo signaling pathways.

The 95 genes enriching PI3K-Akt Signaling Pathway overlapped most significantly with pathways in cancer and also overlapped with additional signaling pathways ([Fig. 2](#f0010){ref-type="fig"}d). Especially interesting were AMPK and mTOR pathways, known to be activated during metabolic stress. Most of these pathways were among the top 64 enriched pathways and accounted for most of the signaling pathways of the top 64. One significant exception was Calcium Signaling Pathway ([Table 1](#t0005){ref-type="table"}). It is significant because this pathway is involved in a unique retrograde signaling cascade responding to \[*Ca*^2+^\]~*c*~ elevation during disruptions of the mitochondrial electron transport chain [@bb0035]. We show in the following sections with specific expression changes that the defect in CcO complex caused metabolic shift to glycolysis, induced calcium dependent retrograde signaling, activated PI3K pathway and resulted in carcinogenesis.

4.2. Disruption of CcO complex leading to metabolic shift to glycolysis {#s0055}
-----------------------------------------------------------------------

The expression of Cox4i1 in the cells with Cox4i1 silenced by shRNA, referred as CcO4KD cells throughout this paper, was less than 5% of the control with scrambled shRNA ([Fig. 3](#f0015){ref-type="fig"}a). The mRNA expression levels of the irreversible glycolytic enzymes, Hexokinase (Hk1, [Fig. 3](#f0015){ref-type="fig"}b), Phosphofructokinae (Pfkm, [Fig. 3](#f0015){ref-type="fig"}c) and Pyruvate kinase (Pkm, [Fig. 3](#f0015){ref-type="fig"}d) had approximately two-folds increase. [Fig. 3](#f0015){ref-type="fig"} also shows the mRNA expression levels of four other enzymes in the glycolytic pathway with the most fold-changes (Acss2, Adh1, Adh7 and Aldh2 in [Fig. 3](#f0015){ref-type="fig"}e to h). They were all up-regulated in CcO4KD cells and are downstream of glycolysis---important for processing pyruvate produced during glycolysis. In agreement with these data, CcO activity was reduced by about 90%, the Hk and Pfk activities increased about two folds, and glucose uptake was more than two-fold higher in CcO4KD cells [@bb0010]. These indicated that silencing Cox4i1 lead to the disruption of CcO activity and caused metabolic shift to glycolysis.

4.3. Activation of Calcium dependent retrograde signaling pathway {#s0060}
-----------------------------------------------------------------

The mitochondrial stress and the loss of mitochondrial membrane potential were indicated by the enrichment of Calcium Signaling Pathway ([Table 1](#t0005){ref-type="table"}) and in particular by a two-fold increase in the expression level of *Ca*^2+^ sensitive Calcineurin (Ppp3ca, [Fig. 4](#f0020){ref-type="fig"}a). This signal in response to sustained elevation of \[*Ca*^2+^\]~*c*~ had been shown to activate a set of stress responsive transcription factors: NFkB, NFAT and CREB [@bb0035]. This was consistent with the increased expression levels of Nfkb1, Nfkb2, Rela, Nfatc1, Nfatc3, Creb3l1 and Creb3l2 ([Fig. 4](#f0020){ref-type="fig"}b to h). In addition to those, this retrograde stress signaling induced increased expression of many genes involved in tumor progression. In particular, Tgfb1 and Mmp16 had 2 to 3 folds expression increase ([Fig. 5](#f0025){ref-type="fig"}a and b). In agreement with these data, Calcineurin activity increased three folds in CcO4KD cells; while for the cells further treated with BAPTA, a *Ca*^2+^ chelator, or FK506, a specific Calcineurin inhibitor, the up-regulation of Tgfb1 and Mmp16 was significantly attenuated and the glucose uptake was significantly inhibited comparing to untreated cells [@bb0010]. These indicated that the Calcineurin mediated retrograde signaling pathway played an important role in metabolic shift to glycolysis and carcinogenesis.

4.4. Activation of PI3-kinase pathway and carcinogenesis {#s0065}
--------------------------------------------------------

The activation of PI3-kinase pathway was indicated by a two-fold increase in expression level of PI3-kinase---of both catalytic and regulatory subunits Pik3cb and Pik3r4 ([Fig. 6](#f0030){ref-type="fig"}a and b). It has been shown that this pathway is a major determinant of the glycolytic phenotype through Akt1 and Mtor signaling and subsequent downstream Hif1a transcription factor activation [@bb0040]. In addition to increased expression of Mtor and Hif1a ([Fig. 6](#f0030){ref-type="fig"}c and d) in CcO4KD cells, there were also increased expression levels for genes further down stream [@bb0045] of this pathway including Redd1(Ddit4), Tsc2, Foxo1 and PKCα(Prkca) ([Fig. 6](#f0030){ref-type="fig"}e to h) as well as other genes related to pathways in cancer ([Fig. 5](#f0025){ref-type="fig"}). Aerobic glycolysis supports various biosynthetic pathways and, consequently, the metabolic requirements for proliferation. Consistent with this, the CcO4KD cells developed anchorage independent growth, an important hallmark of malignant cells, and further treatment with Wortmannin, a PI3-kinase inhibitor, attenuated the glucose uptake and inhibited the colony formation of those cells [@bb0010]. These indicated that the PI3-kinase pathway played a crucial role in metabolic shift to glycolysis and in tumor progression.

4.5. Oncogenes enriched transcription profiles {#s0070}
----------------------------------------------

Bmp4, Arnt2, Tgfb2, Col4a5 and Ar (shown in [Fig. 5](#f0025){ref-type="fig"}c to g) were the five most up-regulated genes in Pathways in Cancer. Ccne1 (shown in [Fig. 5](#f0025){ref-type="fig"}h) was the most down-regulated gene in Pathways in Cancer. Col4a5 and Ccne1 are in PI3K-Akt Pathway and their corresponding up and down regulation are consistent with their role in cancers. Furthermore, Ar, Bmp4 and Tgfb2 are involved in signal transduction and Ar, Arnt2 and Bmp4 are involved in regulation of transcription. To gain additional understanding of functional roles of the most significantly regulated genes of CcO4KD cells, we further narrowed down the list of genes and did functional annotation of the list. There were 1047 genes with 2-fold or more expression change and *p*-value less than 0.01. The distribution of those genes in the three dominate pathways and 10 different functional groups is shown in [Fig. 7](#f0035){ref-type="fig"}a. Among those were 38 significantly regulated genes in Pathways in Cancer (enrichment *p*-value less than 10^− 6^). [Table 2](#t0010){ref-type="table"} shows the fold changes and the *p*-values of the 38 genes. 35 genes in Pathways in Cancer were up-regulated (enrichment *p*-value less than 10^− 5^). 24, 15 and 11 of these up-regulated genes in pathways in cancer are in functional groups of signal transduction, regulation of transcription and PI3K pathway, respectively. There were extensive overlaps (11) between those in signal transduction and regulation of transcription ([Fig. 7](#f0035){ref-type="fig"}b). There were also overlaps (5) between those in signal transduction and PI3K pathway ([Fig. 7](#f0035){ref-type="fig"}c). There was only one (Rxra) overlap between those in regulation of transcription and PI3K pathway. Only two genes (Dapk2 and Ncoa4) in pathways in cancer were not in any of the other three functional groups. Interestingly, none of genes in pathways in cancer was in metabolic pathway. It appears that CcO defects induced Calcineurin/PI3K retrograde signaling which in turns induced up-regulation of genes involved in signal transduction and regulation of transcription, up-regulation of genes related to pathways in cancer, and carcinogenesis.

5. Discussion {#s0075}
=============

The whole genome microarray analysis of the knockdown and control cells gave the insight into the magnitude of systematic changes of gene expressions and also enabled the global analysis of pathways and functional groups of many genes efficiently. It is interesting to know the accuracy of individual fold change of gene expression estimated from the experimental array. For some of the genes, the relative mRNA levels were also measured by RT-PCR [@bb0010]. [Fig. 8](#f0040){ref-type="fig"} shows the comparison between the results of microarray and RT-PCR. The agreement is quite good. The that fold change estimated by the array is slightly on the conservative side. This gave confidence to use the array not only for the global analysis but also for measuring relative change of individual gene\'s mRNA level.

The pathway analysis also indicated that PPAR (PGC-1*α*) signaling pathway was activated. PGC-1*α* is another regulator of mitochondrial biogenesis and function. It has been shown that PGC-1*α* has a positive feedback to one of its upstream regulator: Calcineurin [@bb0050]. This protein can interact with, and regulate the activities of, cAMP response element-binding protein (CREB). [Fig. 9](#f0045){ref-type="fig"}a to d shows the up-regulation of PGC-1*α* (Ppargc1a) and its interaction partners Crebbp, Pparg, and Rxra. Another important pathway activated was the AMP-activated protein kinase (AMPK) signaling pathway. AMPK plays an important role in insulin signaling, glucose uptake, and energy homeostasis and is involved in PGC-1*α*-mediated mitochondrial biogenesis. The microarray analysis indicated up-regulation of AMPK (Prkaa1 and Prkaa2 in [Fig. 9](#f0045){ref-type="fig"}e and f) and its up-stream regulator LKB1 (Stk11, [Fig. 9](#f0045){ref-type="fig"}g) as well as two downstream genes (Srebf1, [Fig. 9](#f0045){ref-type="fig"}h; and Tsc2, [Fig. 6](#f0030){ref-type="fig"}f). This is puzzling since AMPK is supposed to down-regulated Srebf1 and Tsc2 and to be a metabolic checkpoint to control cell proliferation when activated under energy stress. But it was not doing any of those in CcO4KD cells. The role of AMPK pathway in Cox4i1 knockdown needs to be studied further.

Our physiological experiments have shown that CcO dysfunction is a possible biomarker for cancer progression in digestive diseases such as esophageal tumors [@bb0010]. It will be very interesting to conduct a whole genome expression analysis on such tumors and to compare the results with those presented in this paper. Such comparison will help to further understand the pathways of this type of tumor progression and to find possible pathway-based methods of diagnosis and treatment.

This work was supported by NIH grant CA-22762, NIH/NIDDK Center grant P30DK050306, and a grant from Research Foundation, University of Pennsylvania.

![Quality control for data analysis. The array expression data (from all 41,345 probes) of each sample are projected to the first two components of PCA, P1 and P2 in **a**, showing the separation of 6 samples into three groups. This separation is also shown in the 6 × 6 matrix of the correlation coefficients between samples (**b**). The plot in (**c**) shows the selection criteria for significant fold change in individual gene expression: the absolute fold change has to be bigger than 2^0.5^ (red and blue dots), and the *p*-value has to be smaller than 0.05. For functional analysis, the selected genes are ranked by *p*-value and are further selected by Benjamini-Hocheberg method to limit FDR (**d**).](gr1){#f0005}

![Three major pathways of significantly regulated genes of CcO4KD cells---Metabolic Pathways, Pathways in Cancer and PI3K-Akt Signaling Pathway: **a**, overlaps between the three; **b**, Metabolic Pathways\' overlaps with others; **c**, Pathways in Cancer\'s overlaps with others; **d**, PI3K-Akt Signaling Pathway\'s overlaps with others.](gr2){#f0010}

![Knock-down of the expression level of cytochrome c oxidase (Cox4i1 in **a**), and expression up-regulation of all three irreversible glycolytic enzymes Hexokinase (Hk1 in **b**), Phosphofructokinase (Pfkm in **c**) and Pyruvate Kinase (Pkm in **d**), as well as four other enzymes downstream of glycolysis: Acss2, Adh1, Adh7 and Aldh2 (**e**, **f**, **g** and **h**).](gr3){#f0015}

![Up-regulation of Calcineurin (Ppp3ca in **a**) and Calcineurin pathway: NFkB (Nfkb1 in **b**, Nfkb2 in **c** and Rela in **d**), NFAT (Nfatc1 in **e** and Nfatc3 in **f**), and CREB (Creb3l1 in **g** and Creb3l2 in **h**).](gr4){#f0020}

![Up-regulation of seven genes related to cancer: Tgfb1 in **a**, Mmp16 in **b**, Ar in **c**, Col4a5 in **d**, Tgfb2 in **e**, Arnt2 in **f** and Bmp4 in **g**. Down-regulation of one gene related to cancer: Ccne1 in **h**.](gr5){#f0025}

![Up-regulation of PI3-kinase (Pik3cb in **a** and Pik3r4 in **b**) and PI3-kinase pathway: Mtor in **c**, Hif1a in **d**, Ddit4 in **e**, Tsc2 in **f**, Foxo1 in **g**, and Prkca in **h**.](gr6){#f0030}

![Functional groups of significantly regulated genes of CcO4KD cells: **a**, the number of genes with significant fold-changes in different functional groups; **b**, the Venn diagrams of up-regulated genes in signal transduction (pink), regulation of transcription (green) and pathways in cancer (brown); **c**, the Venn diagrams of up-regulated genes in signal transduction (pink), PI3K pathway (green) and pathways in cancer (brown).](gr7){#f0035}

![The comparison between the expression fold changes of four genes from microarray and those measured by RT-PCR in a log-log plot. The straight line lies where they are equal.](gr8){#f0040}

![Up-regulation of PGC-1*α* (Ppargc1a in **a**) and its interaction partners: Crebbp in **b**, Pparg in **c**, and Rxra in **d**. Up-regulation of AMPK (Prkaa1 in **e** and Prkaa2 in **f**), its upstream regulator LKB1 (Stk11 in **g**) and a downstream gene Srebf1 in **h**.](gr9){#f0045}

###### 

Top 64 most enriched pathways in the C4KD cells compared to the control cells.

The top pathways were selected with the number of hits ≥ 20 and the *p*-value \< 0.15.

  Hits   Size   \%   *p*-value   Kegg id   Name of pathway
  ------ ------ ---- ----------- --------- ----------------------------------------------------------
  330    1271   26   1.3e-11     01100     Metabolic pathways
  127    397    32   6.4e-11     05200     Pathways in cancer
  95     352    27   5.3-e05     04151     PI3K-Akt signaling pathway
  74     232    32   6.3e-07     05203     Viral carcinogenesis
  73     206    35   6.1e-09     05205     Proteoglycans in cancer
  71     276    26   1.8e-03     05206     MicroRNAs in cancer
  68     254    27   7.2e-04     04010     MAPK signaling pathway
  66     208    32   3.0e-06     04510     Focal adhesion
  64     170    38   3.4e-09     03013     RNA transport
  64     218    29   6.3e-05     01130     Biosynthesis of antibiotics
  64     235    27   6.3e-04     04144     Endocytosis
  60     145    41   1.1e-10     03010     Ribosome
  58     230    25   6.9e-03     04014     Ras signaling pathway
  54     214    25   8.7e-03     04015     Rap1 signaling pathway
  50     133    38   1.8e-07     03040     Spliceosome
  49     118    42   5.5e-09     04919     Thyroid hormone signaling pathway
  48     177    27   3.0e-03     05202     Transcriptional misregulation in cancer
  45     168    27   5.1e-03     04141     Protein processing in endoplasmic reticulum
  45     172    26   8.1e-03     04022     cGMP-PKG signaling pathway
  45     179    25   1.7e-02     00230     Purine metabolism
  44     198    22   1.1e-01     04062     Chemokine signaling pathway
  43     139    31   2.7e-04     00190     Oxidative phosphorylation
  43     143    30   5.4e-04     04120     Ubiquitin mediated proteolysis
  41     142    29   1.7e-03     04910     Insulin signaling pathway
  41     129    32   2.0e-04     04152     AMPK signaling pathway
  41     174    24   5.5e-02     04145     Phagosome
  40     181    22   1.3e-01     04020     Calcium signaling pathway
  40     143    28   3.6e-03     04310     Wnt signaling pathway
  39     159    25   3.5e-02     04921     Oxytocin signaling pathway
  39     125    31   4.3e-04     04110     Cell cycle
  38     154    25   3.4e-02     04390     Hippo signaling pathway
  37     104    36   2.8e-05     00240     Pyrimidine metabolism
  37     124    30   1.5e-03     04142     Lysosome
  37     103    36   2.2e-05     04922     Glucagon signaling pathway
  36     134    27   1.1e-02     04068     FoxO signaling pathway
  35     122    29   4.0e-03     04722     Neurotrophin signaling pathway
  35     115    30   1.3e-03     04114     Oocyte meiosis
  34     140    24   5.2e-02     04530     Tight junction
  33     140    24   7.8e-02     04550     Signaling pathways regulating pluripotency of stem cells
  31     94     33   5.6e-04     00564     Glycerophospholipid metabolism
  30     109    28   1.3e-02     04066     HIF-1 signaling pathway
  29     101    29   8.1e-03     05231     Choline metabolism in cancer29
  29     117    25   5.5e-02     01200     Carbon metabolism
  28     124    23   1.5e-01     04071     Sphingolipid signaling pathway
  27     87     31   3.3e-03     04540     Gap junction
  26     88     30   7.9e-03     04512     ECM-receptor interaction
  26     96     27   2.5e-02     03015     mRNA surveillance pathway
  25     83     30   7.0e-03     03008     Ribosome biogenesis in eukaryotes
  25     99     25   5.9e-02     04915     Estrogen signaling pathway
  25     67     37   2.3e-04     04115     p53 signaling pathway
  25     89     28   1.8e-02     04912     GnRH signaling pathway
  25     82     30   5.9e-03     04210     Apoptosis
  25     72     35   8.0e-04     04920     Adipocytokine signaling pathway
  23     74     31   6.3e-03     04520     Adherens junction
  23     87     26   4.3e-02     04012     ErbB signaling pathway
  23     83     28   2.6e-02     03018     RNA degradation
  23     82     28   2.2e-02     003320    PPAR signaling pathway
  22     74     30   1.3e-02     04917     Prolactin signaling pathway
  22     82     27   4.0e-02     04070     Phosphatidylinositol signaling system
  22     66     33   2.9e-03     05230     Central carbon metabolism in cancer
  21     82     26   6.9e-02     04350     TGF-beta signaling pathwa
  20     79     25   8.2e-02     01230     Biosynthesis of amino acids
  20     66     30   1.4e-02     00010     Glycolysis / Gluconeogenesis
  20     61     33   5.4e-03     04150     mTOR signaling pathway

###### 

38 significantly regulated genes in pathways in cancer. 35 were up-regulated in CcO4KD and only 3 were down-regulated (Ccne1, Ccne2 and Tceb1). The genes were selected with a fold change ≥ 2 and a *p*-value \< 0.01. The fold change is expressed in *log*~2~ unit.

  Symbol   Fold     *p*-Value   Entrez    Gene name
  -------- -------- ----------- --------- --------------------------------------------------------------------
  Ar       1.65     2e-04       11,835    Androgen receptor
  Arnt2    2.45     1e-03       11,864    Aryl hydrocarbon receptor nuclear translocator 2
  Bmp4     3.25     3e-04       12,159    Bone morphogenetic protein 4
  Ccne1    − 1.12   1e-03       12,447    Cyclin E1
  Ccne2    − 1.09   3e-04       12,448    Cyclin E2
  Cebpa    1.54     2e-03       12,606    CCAAT/enhancer binding protein (C/EBP), *α*
  Col4a2   1.45     2e-04       12,827    Collagen, type IV, *α* 2
  Col4a5   1.69     1e-03       12,830    Collagen, type IV, *α* 5
  Col4a6   1.02     1e-04       94,216    Collagen, type IV, *α* 6
  Dapk2    1.45     1e-03       13,143    Death-associated protein kinase 2
  Ep300    1.03     2e-05       328,572   E1A binding protein p300
  Figf     1.31     1e-03       14,205    c-fos induced growth factor
  Foxo1    1.32     1e-03       56,458    Forkhead box O1
  Fzd4     1.08     4e-03       14,366    Frizzled homolog 4 (Drosophila)
  Fzd6     1.56     4e-03       14,368    Frizzled homolog 6 (Drosophila)
  Gli2     1.07     5e-03       14,633    GLI-Kruppel family member GLI2
  Jak1     1.02     2e-05       16,451    Janus kinase 1
  Kitl     1.46     2e-03       17,311    Kit ligand
  Lama2    1.49     1e-04       16,773    Laminin, *α* 2
  Lamb3    1.35     6e-04       16,780    Laminin, *β* 3
  Lamc1    1.18     3e-05       226,519   Laminin, *γ* 1
  Met      1.13     2e-03       17,295    Met proto-oncogene
  Ncoa4    1.05     2e-04       27,057    Nuclear receptor coactivator 4
  Nfkb2    1.03     9e-04       18,034    Nuclear factor of *κ* light polypeptide gene enhancer in B cells 2
  Pdgfb    1.74     8e-04       18,591    Platelet derived growth factor, B polypeptide
  Ppard    1.15     9e-04       19,015    Peroxisome proliferator activator receptor delta
  Rxra     1.03     2e-04       20,181    Retinoid X receptor *α*
  Stat1    1.23     1e-03       20,846    Signal transducer and activator of transcription 1
  Stat5a   1.02     1e-04       20,850    Signal transducer and activator of transcription 5A
  Tceb1    − 1.09   1e-03       67,923    Transcription elongation factor B (SIII), polypeptide 1
  Tcf7     1.16     6e-03       21,414    Transcription factor 7, T cell specific
  Tcf7l2   1.05     4e-05       21,416    Transcription factor 7 like 2, T cell specific, HMG box
  Tgfb1    1.00     6e-04       21,803    Transforming growth factor, *β* 1
  Tgfb2    2.27     1e-05       21,808    Transforming growth factor, *β* 2
  Tgfbr2   1.36     4e-05       21,813    Transforming growth factor, *β* receptor II
  Wnt10a   1.58     9e-04       22,409    Wingless related MMTV integration site 10a
  Wnt4     1.16     7e-03       22,417    Wingless-related MMTV integration site 4
  Wnt7b    1.40     3e-04       22,422    Wingless-related MMTV integration site 7B
